Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphomaAlison J Moskowitz, Paul A Hamlin, Miguel-Angel Perales, et al.
British Journal of Haematology|October 4, 2007
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphomaOwen A O'Connor, Paul A Hamlin, Carol Portlock, et al.
American Journal of Hematology|May 19, 2020
ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European studyPatrizia Mondello, Caterina Musolino, Irene Dogliotti, et al.
Blood|March 1, 2011
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PETDavid J Straus, Jeffrey L Johnson, Ann S LaCasce, et al.
Blood Cancer Journal|May 22, 2019
Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapseAnita Kumar, Fushen Sha, Ahmed Toure, et al.
Blood Advances|January 26, 2021
Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissueErel Joffe, Yan Leyfman, Esther Drill, et al.
Blood|July 28, 2018
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PETDavid J Straus, Sin-Ho Jung, Brandelyn Pitcher, et al.
Blood|February 2, 2018
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCLCraig S Sauter, Matthew J Matasar, Heiko Schoder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2019
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin LymphomaRadhakrishnan Ramchandren, Ranjana H Advani, Stephen M Ansell, et al.
Blood|July 24, 2019
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphomaDeborah M Stephens, Hongli Li, Heiko Schöder, et al.
Pageof 6